Cargando…

The role of GSK-3 in mood disorders: Preliminary data from an experimental study

INTRODUCTION: The identification of potential biomarkers is crucial to improve the management and treatment of mood disorders. Glycogen synthase kinase-3 (GSK-3) is a multifunctional enzyme with an important role in the etiology of mood disorders. Recent findings suggested GSK-3 as a putative biomar...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvo, G. Di, Rosso, G., Hoxha, E., Teobaldi, E., Balbo, I., Tempia, F., Maina, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475711/
http://dx.doi.org/10.1192/j.eurpsy.2021.1025
_version_ 1784789971700285440
author Salvo, G. Di
Rosso, G.
Hoxha, E.
Teobaldi, E.
Balbo, I.
Tempia, F.
Maina, G.
author_facet Salvo, G. Di
Rosso, G.
Hoxha, E.
Teobaldi, E.
Balbo, I.
Tempia, F.
Maina, G.
author_sort Salvo, G. Di
collection PubMed
description INTRODUCTION: The identification of potential biomarkers is crucial to improve the management and treatment of mood disorders. Glycogen synthase kinase-3 (GSK-3) is a multifunctional enzyme with an important role in the etiology of mood disorders. Recent findings suggested GSK-3 as a putative biomarker in mood disorders. OBJECTIVES: The aims of the study are: - to evaluate GSK3 as potential biomarker for differential diagnosis (MDD and BD); - to analyze the regulation of GSK3 by psychopharmacological treatments. METHODS: Patients included fulfill the following criteria: (a) principal diagnosis of MDD or BD (DSM-5); (b) age ≥ 18 years; (c) drug-free for at least 4 weeks before the inclusion. For each patient included a healthy control is enrolled, matched by gender and age. All included subjects at the study entry point (t0) are assessed through: - semistructured clinical interview and clinical rating scales (Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale; Young Mania Rating Scale, Clinical Global Impression) - blood draw, to measure GSK-3 levels Patients with MDD or BD are assessed again after 1 week (T1) and after 2 month (T2) of specific pharmacological treatment. RESULTS: So far, we enrolled 16 patients and 16 healthy controls. The enrollment is still ongoing. CONCLUSIONS: We expect to find GSK-3 levels differently expressed between healthy controls, patients with DDM and patients with BD. This finding would be crucial as it could contribute to the improvement of differential diagnosis. Moreover, we expect to observe a change in GSK-3 levels after psychopharmacological treatments.
format Online
Article
Text
id pubmed-9475711
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94757112022-09-29 The role of GSK-3 in mood disorders: Preliminary data from an experimental study Salvo, G. Di Rosso, G. Hoxha, E. Teobaldi, E. Balbo, I. Tempia, F. Maina, G. Eur Psychiatry Abstract INTRODUCTION: The identification of potential biomarkers is crucial to improve the management and treatment of mood disorders. Glycogen synthase kinase-3 (GSK-3) is a multifunctional enzyme with an important role in the etiology of mood disorders. Recent findings suggested GSK-3 as a putative biomarker in mood disorders. OBJECTIVES: The aims of the study are: - to evaluate GSK3 as potential biomarker for differential diagnosis (MDD and BD); - to analyze the regulation of GSK3 by psychopharmacological treatments. METHODS: Patients included fulfill the following criteria: (a) principal diagnosis of MDD or BD (DSM-5); (b) age ≥ 18 years; (c) drug-free for at least 4 weeks before the inclusion. For each patient included a healthy control is enrolled, matched by gender and age. All included subjects at the study entry point (t0) are assessed through: - semistructured clinical interview and clinical rating scales (Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale; Young Mania Rating Scale, Clinical Global Impression) - blood draw, to measure GSK-3 levels Patients with MDD or BD are assessed again after 1 week (T1) and after 2 month (T2) of specific pharmacological treatment. RESULTS: So far, we enrolled 16 patients and 16 healthy controls. The enrollment is still ongoing. CONCLUSIONS: We expect to find GSK-3 levels differently expressed between healthy controls, patients with DDM and patients with BD. This finding would be crucial as it could contribute to the improvement of differential diagnosis. Moreover, we expect to observe a change in GSK-3 levels after psychopharmacological treatments. Cambridge University Press 2021-08-13 /pmc/articles/PMC9475711/ http://dx.doi.org/10.1192/j.eurpsy.2021.1025 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Salvo, G. Di
Rosso, G.
Hoxha, E.
Teobaldi, E.
Balbo, I.
Tempia, F.
Maina, G.
The role of GSK-3 in mood disorders: Preliminary data from an experimental study
title The role of GSK-3 in mood disorders: Preliminary data from an experimental study
title_full The role of GSK-3 in mood disorders: Preliminary data from an experimental study
title_fullStr The role of GSK-3 in mood disorders: Preliminary data from an experimental study
title_full_unstemmed The role of GSK-3 in mood disorders: Preliminary data from an experimental study
title_short The role of GSK-3 in mood disorders: Preliminary data from an experimental study
title_sort role of gsk-3 in mood disorders: preliminary data from an experimental study
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475711/
http://dx.doi.org/10.1192/j.eurpsy.2021.1025
work_keys_str_mv AT salvogdi theroleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT rossog theroleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT hoxhae theroleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT teobaldie theroleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT balboi theroleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT tempiaf theroleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT mainag theroleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT salvogdi roleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT rossog roleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT hoxhae roleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT teobaldie roleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT balboi roleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT tempiaf roleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy
AT mainag roleofgsk3inmooddisorderspreliminarydatafromanexperimentalstudy